Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases

International Journal of Radiation Oncology Biology Physics

Volumn 95, Issue 2, 2016, Pages 673-679

  Magnuson, William J ^a   Yeung, Jacky T ^a   Guillod, Paul D ^a   Gettinger, Scott N ^a   Yu, James B ^a   Chiang, Veronica L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; BRAIN; PATHOLOGY; PATIENT MONITORING; RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTORS; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; RANDOMIZED TRIAL; RETROSPECTIVE ANALYSIS; TYROSINE KINASE INHIBITOR; WHOLE BRAIN RADIATION THERAPIES;

PATIENT TREATMENT;

AFATINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; NIVOLUMAB; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODAL CHEMOTHERAPY; NEUROIMAGING; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; RADIOSURGERY; SALVAGE THERAPY; SECONDARY; SKULL IRRADIATION;

ADULT; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84962268917     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.01.037     Document Type: Article

References (38)

1. L.A. Torre, F. Bray, R.L. Siegel, and et al. Global cancer statistics, 2012 CA Cancer J Clin 65 2015 87 108
2. J.S. Barnholtz-Sloan, A.E. Sloan, F.G. Davis, and et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System J Clin Oncol 22 2004 2865 2872
3. D.Y. Shin, I.I. Na, C.H. Kim, and et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas J Thorac Oncol 9 2014 195 199
4. A.F. Eichler, E. Chung, D.P. Kodack, and et al. The biology of brain metastases-translation to new therapies Nat Rev Clin Oncol 8 2011 344 356
5. S. Khozin, G.M. Blumenthal, X. Jiang, and et al. U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (l858r) substitution mutations Oncologist 19 2014 774 779
6. Y. Deng, W. Feng, J. Wu, and et al. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer Mol Clin Oncol 2 2014 116 120
7. Y.D. Zeng, H. Liao, T. Qin, and et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy Oncotarget 6 2015 8366 8376
8. P.E. Postmus, and E.F. Smit Chemotherapy for brain metastases of lung cancer: A review Ann Oncol 10 1999 753 759
9. S.J. Park, H.T. Kim, D.H. Lee, and et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer 77 2012 556 560
10. R. Rosell, T. Moran, C. Queralt, and et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
11. T. Iuchi, M. Shingyoji, T. Sakaida, and et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma Lung Cancer 82 2013 282 287
12. N.N. Laack, and P.D. Brown Cognitive sequelae of brain radiation in adults Semin Oncol 31 2004 702 713
13. D.H. Lee, J.Y. Han, H.T. Kim, and et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: Result of a randomized pilot study Cancer 113 2008 143 149
14. P.W. Sperduto, N. Kased, D. Roberge, and et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases J Clin Oncol 30 2012 419 425
15. D.W. Andrews, C.B. Scott, P.W. Sperduto, and et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial Lancet 363 2004 1665 1672
16. E. Shaw, C. Scott, L. Souhami, and et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05 Int J Radiat Oncol Biol Phys 47 2000 291 298
17. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
18. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. J.W. Welsh, R. Komaki, A. Amini, and et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer J Clin Oncol 31 2013 895 902
20. Y.L. Wu, C. Zhou, Y. Cheng, and et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803) Ann Oncol 24 2013 993 999
21. S. Hellman, and R.R. Weichselbaum Oligometastases J Clin Oncol 13 1995 8 10
22. A.B. Ashworth, S. Senan, D.A. Palma, and et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer Clin Lung Cancer 15 2014 346 355
23. U. Pastorino, M. Buyse, G. Friedel, and et al. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases J Thorac Cardiovasc Surg 113 1997 37 49
24. A. Ashworth, G. Rodrigues, G. Boldt, and et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature Lung Cancer 82 2013 197 203
25. M.T. Milano, A.W. Katz, H. Zhang, and et al. Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study Int J Radiat Oncol Biol Phys 83 2012 878 886
26. R. Rami-Porta, J.J. Crowley, and P. Goldstraw The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 2009 4 9
27. H.A. Yu, C.S. Sima, J. Huang, and et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 8 2013 346 351
28. N.K. Gerber, Y. Yamada, A. Rimner, and et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma Int J Radiat Oncol Biol Phys 89 2014 322 329
29. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
30. C.H. Gow, C.R. Chien, Y.L. Chang, and et al. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response Clin Cancer Res 14 2008 162 168
31. K.L. Johung, X. Yao, F. Li, and et al. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer Clin Cancer Res 19 2013 5523 5532
32. M.M. El Gantery, H.M. Abd El Baky, H.A. El Hossieny, and et al. Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both Radiat Oncol 9 2014 116
33. L.E. Hendriks, E.G. Troost, A. Steward, and et al. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases Acta Oncol 53 2014 945 951
34. R. Soffietti, M. Kocher, U.M. Abacioglu, and et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results J Clin Oncol 31 2013 65 72
35. M. Kocher, R. Soffietti, U. Abacioglu, and et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study J Clin Oncol 29 2011 134 141
36. V. Gondi, S.L. Pugh, W.A. Tome, and et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial J Clin Oncol 32 2014 3810 3816
37. P.D. Brown, S. Pugh, N.N. Laack, and et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial Neuro Oncol 15 2013 1429 1437
38. C.H. Gow, Y.L. Chang, Y.C. Hsu, and et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer Ann Oncol 20 2009 696 702